Atri injection / Atri plus injection CE renewal [SZU] Turkey
2019
2019.12.6
Excellence in Brand award - Mayor of Seoul Award
2019.5.15
Released DivaViva Series, a Dermal HA Filler that is Independently developed/completed clinical trial
2019.2.21
Kenya PPB GMP approval
2019.1.1
Obtained the Ministry of Employment and Labor certification of "Youth-friendly Hidden Champion" business
2018
2018.11.29
Obtained the Ministry of Gender Equality and Family cerftification of "Family Friendly Business"
2018.10.24
Renewal of GMP Inspection by JAPAN PMDA for Oral Solid Dosage
2018.4.16
Chosen as "Hi Seoul PR Grand Prix" by The Korea Economic Daily
2018.2.5
Signed BEMFOLA license contract
2017
2017.10.26
Chosen as "2017 Export Grand Prix" by Chungcheongbuk-do government
2017.8.25
CE/ISO 13485 renewal
2017.6.8
Obtained INNO-BIZ certification from Ministry of Small and Medium Business Administration
2016
2016.12.7
Signed a license contract for SIMDAX
2016.12.5
Awarded of "5 million dollar export tower" at Trade day
2016.10.25
Selected as "Company with Excellent Quality Management" by Chungcheongbuk-do government
2015
2015.2.1
Release of the world's first stem cell treatment for Lou Gheric's disease, NeuroNata-R®
2014
2014.1.9
Merge/Expansion of central research center(bio research/formulation research)
2013
2013.9.12
Earned a Certification of Best HRD in 2013
(certified by Ministry of Employment and Labor, Ministry of Education, Ministry of Trade, Industry and Energy, and Ministry of Small and Medium Business Administration)
2013.2.26
Signed a technology license-in contract for the development of YY1201 with Novozyme
2013.2.8
Signed a technology transfer contract for YYB-101, an antibody novelty medication with National Onco Venture
2012
2012.10.5
Signed an exclusive sales contract of Atri plus injection in EU
2012.10.4
Released Pravafenix Capsule
2012.4.17
Atri injection and Atri plus Injection, treatments for osteoarthritis, obtained CE Mark
2011
2011.10.4
GMP Inspection by JAPAN PMDA for the Injections
2011.4.7
Awarded recognition by the Minister of Health and Welfare
2011.3.22
Corestem - Signed a contract for co-research effort and licensure for stem cell cure for Lou Gehric's Disease
2010
2010.12.1
Selected as "promising small business for export" by Chungbuk Ministry of SMEs and Startups
2010.11.4
Day of Chungbuk Businessman - selected as a company exhibiting"Excellence in Labor-Management Cooperation"
2009
2009.12.2
Awarded of "1 million dollar export tower" at Trade day
2009.11.10
SMB, made an agreement for Hyperlipidemia combination agent (Pravafenix)
2009.10.26
GMP Inspection by JAPAN PMDA for Oral Solid Dosage
2008
2008.8.28
Awarded of an appreciation plaque by the Minister of Health and Welfare
Initiated construction of factory in Jincheon in compliance of EU-GMP standard
2007.2.1
Mr. Woopyong Yoo became the CEO
2006
2006.12.12
KSGP Certification by Ministry of Food and Drug Safety Administration, No. 1543
2005
2005.9.2
Initiated expansion construction of the 2nd manufacturing plant in Jincheon
2005.5.17
Selected as an exemplary small business, received President's award
2003
2003.7.18
Daejeon - Korean Ministry of Food and Drug Safety Administration No. 2003-6 Recognition of Excellence for Drug Product/Drug Substance Part, self-audit evaluation
2003.4.25
Headquarter office moved to Yooyoung Building, 915-9 Bangbae 1-dong, Seocho-gu, Seoul
2003.3.3
Selected as an exemplary taxpayer for the 37th Taxpayer's day; awarded with Stone Tower Order of Industrial Merit
1994
1994.7.7
KOITA No. 941161, Company-affiliated Central Research Center Established
1991
1991.4.9
The Minister of Health and Welfare approval No. 62, KGMP certified
1990
1990.4.21
Main branch and KGMP factory construction and moving (492-17, Jukhyeon-ri, Gwanghyewon-myeon, Jincheon-gun, Chungchungbuk-do)
1982
1982.6.18
New factory construction and moving (609-1, Yangok-ri, Yangchon-myeon, Gimpo-si, Gyeonggi-do)
1981
1981.12.23
Hanjoong Pharmaceuticals Co. Ltd. Merger and name change Mr. Youngsoh Yoo became the first president
